|
|||||
|
|
Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin,in recurrent glioblastoma |
|
| Authors: | David Schiff Santosh Kesari John de Groot Tom Mikkelsen Jan Drappatz Thomas Coyle Lisa Fichtel Bruce Silver Ian Walters David Reardon |
| Affiliation: | 1. University of Virginia Neuro-Oncology Center, Box 800432, Charlottesville, VA, 22908-0432, USA 2. Dana-Farber Cancer Institute, Boston, MA, USA 3. M.D. Anderson Cancer Center, Houston, TX, USA 4. Henry Ford Hospital, Detroit, MI, USA 5. State University of New York Upstate Medical University, Syracuse, NY, USA 6. South Texas Oncology and Hematology, San Antonio, TX, USA 7. Adnexus, A BMS R&D Company, Waltham, MA, USA 8. Bristol-Myers Squibb, Wallingford, CT, USA 9. Duke University, Durham, NC, USA |
| Abstract: | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |